Earnings ·
Viatris Inc. reported second-quarter 2026 financial results, delivering total revenues of $3.8 billion, a 5% increase…
VTRSViatris Inc
Viatris Inc. reported second-quarter 2026 financial results, delivering total revenues of $3.8 billion, a 5% increase from the prior year period. The company posted a U.S. GAAP net loss of $119 million and adjusted EPS of $0.69. Adjusted EBITDA rose 8% operationally to $1.2 billion. Viatris raised its full-year 2026 guidance midpoints for total revenues, adjusted EBITDA, adjusted EPS, and free cash flow. The company returned approximately $550 million to shareholders through capital returns, including $270 million in share repurchases, while reducing its gross leverage ratio to 2.9x. Key operational developments include the FDA approval of Gwyn Lo, a new contraceptive patch, and the sale of global rights for Tyrvaya to Harrow, Inc. Manufacturing disruptions at its Nashik, India facility are expected to impact second-half revenues by $100 million to $150 million due to remediation activities following a fire and FDA observations. Viatris is a global healthcare company that develops, manufactures, and markets generic medicines, biosimilars, and innovative branded therapies.